In September 2020, MindMed announced their application to list on the Nasdaq. Speaking to Psilocybin Alpha, CEO and Co-founder JR Rahn explained his hopes that the move would give the company further access to U.S. capital markets, hot on the heels of COMPASS Pathways’ $146.6m IPO. Today, the company fulfills that ambition, listing on the Nasdaq under ticker symbol MNMD. As such…


Previous articlePsyBio and Miami University Broaden Partnership Agreement for the Continued Advancement of its Neuropsychiatric Drug Discovery Platform, Expediting its IND Submission to the FDA
Next articlePT241 – Nick Meyers and Tyler Chandler of “Dosed”: Iboga and The Opioid Crisis